{"id":"W4200142029","doi":"10.1016/j.annonc.2021.10.139","title":"120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; Eisai","keywords":"Medicine; Pembrolizumab; Internal medicine; First line treatment; Oncology; First line; Population; Placebo; Tolerability; Stock options; Phases of clinical research; Metastatic melanoma; Clinical trial; Adverse effect; Cancer; Chemotherapy; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001330532,0.001501652,0.002829064,0.0005070599,0.0004868337,0.00119619,0.0008857256,0.001586321,0.004870511],"category_scores_gemma":[0.000778393,0.0008038948,0.001478686,0.0004723667,0.001193703,0.00134201,0.0004013957,0.003622949,0.001418741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007907083,"about_ca_system_score_gemma":0.001387851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008700088,"about_ca_topic_score_gemma":0.001804062,"domain_scores_codex":[0.9995315,0.0001868781,0.00002712253,0.00009326399,0.00004154461,0.0001196351],"domain_scores_gemma":[0.9995708,0.0001014321,0.0000527985,0.00003611969,0.00002712732,0.000211731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9340732,0.02544447,0.0006286809,0.0006523381,0.000853205,0.00003603199,0.00004825321,0.0004130434,0.007978745,0.0001360907,0.0008728058,0.02886305],"study_design_scores_gemma":[0.8827448,0.1136871,0.001330388,0.00002046859,0.0003510392,0.00002772445,0.00001523823,0.0003600734,0.0008011134,0.00007928486,0.0005684571,0.00001424475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893689,0.003473027,0.0005917384,0.0003868704,0.0004314281,0.002687764,0.0007322139,0.0001269942,0.002201124],"genre_scores_gemma":[0.9872125,0.002954357,0.001285291,0.0009292748,0.0003686196,0.003003217,0.0009917035,0.00003296005,0.003222213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004870511,"threshold_uncertainty_score":0.01629347,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1440297160081384,"score_gpt":0.4343394679977686,"score_spread":0.2903097519896302,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}